• Disodium bicinchoninate in ROS and Cell Assays

  2026-08-16

  Disodium bicinchoninate brings an aqueous, low-organic-solvent option to protein-normalization and chelation workflows supporting inflammatory cell studies. This guide translates the KGN-cell nanoparticle study into practical assay design, with preparation parameters, matrix controls, and troubleshooting strategies.

• HyperFluor™ 488 Rabbit Anti-Goat IgG Workflow

  2026-08-15

  Translate goat-primary immunodetection into bright, flexible readouts for replication-organelle imaging, Western blotting, flow cytometry, and tissue staining. This Alexa Fluor 488 conjugated secondary antibody is especially useful when FXR-associated membrane organization must be compared across cell populations and assay formats.

• PGE2-Driven Schwann Cell Dedifferentiation in PDAC

  2026-08-15

  Wang et al. identify a paracrine PTGES–PGE2 axis that drives Schwann cell dedifferentiation and promotes perineural invasion in pancreatic ductal adenocarcinoma. By combining clinical multi-omics with coculture and three-dimensional functional models, the study connects tumor-derived prostaglandin signaling to Schwann cell remodeling, LIF and ADAMTS-1 secretion, and directional tumor–nerve interactions.

• Individual SGLT2 Inhibitors in Diabetes and Heart Failure

  2026-08-14

  This systematic review and network meta-analysis compared five individual SGLT2 inhibitors in patients with type 2 diabetes and heart failure, rather than treating the drug class as therapeutically uniform. The findings support substantial heart-failure hospitalization reductions across the class while indicating more limited certainty for differences in composite cardiovascular outcomes between individual agents.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ) Guide

  2026-08-14

  This scenario-driven guide explains how EZ Cap™ Mouse IL-12 mRNA (m1Ψ), SKU R1058, can improve experimental control when researchers assess immune-cell viability, proliferation, or cytotoxicity. It connects transcript design, handling, assay controls, interpretation, and extrahepatic delivery evidence without conflating product specifications with independent performance claims.

• (-)-Arctigenin for NF-κB and MEK1 Workflows

  2026-08-13

  Build reproducible inflammation, signaling, and tumor-microenvironment assays with (-)-Arctigenin, a small-molecule tool spanning iNOS/NF-κB and MEK1-linked experiments. This workflow also shows how to use pharmacological pathway modulation alongside the macrophage EV–miR-660 model without confusing pathway convergence with proof of direct targeting.

• Hypoxia–S100A10 Signaling in Glioblastoma

  2026-08-13

  This study identifies hypoxia-induced S100A10 as a molecular link between the glioblastoma microenvironment, aggressive growth, altered glycolysis, and temozolomide resistance. By integrating public genomic data with cellular proliferation, apoptosis, metabolism, and signaling assays, the work positions S100A10–PI3K-AKT activity as a potential mechanistic axis for further investigation.

• MEDUSA Reveals Hidden Mechanisms of Drug-Induced Death

  2026-08-12

  Honeywell and colleagues introduce MEDUSA, a time-resolved, simulation-assisted framework that separates drug-associated growth effects from cell-death effects in pooled functional genomic screens. Applied to DNA damage, the method identified a p53-dependent switch from apoptosis to a respiration-requiring nonapoptotic death program, showing how death-rate analysis can improve mechanism-of-action and resistance studies.

• RITA (NSC 652287) Assay Workflow Guide

  2026-08-11

  RITA (NSC 652287) combines MDM2-p53 pathway activation with DNA cross-linking activity, making it useful for mechanism-aware cancer studies rather than single-endpoint viability screens. This guide shows how to separate cytostasis from cell death, optimize dose and timing, and connect renal carcinoma research findings with tumor xenograft model design.

• PEI-Modified Laminarin Nanoparticles Enhance OVA Immunity

  2026-08-10

  The reference study developed polyethyleneimine-modified cationic laminarin nanoparticles that combine ovalbumin delivery with adjuvant activity, promoting dendritic-cell activation, lysosomal escape, and antigen cross-presentation. Compared with aluminum adjuvant, the formulation produced stronger antibody and cellular immune responses, although further work is needed to define dose, safety, and translational performance.

• Intravenous Cefazedone PK/PD in CAP

  2026-08-09

  This small prospective study linked intravenous cefazedone exposure with pathogen susceptibility and clinical outcomes in mild to moderate community-acquired pneumonia. Its main contribution was showing that a 2 g every 12 hours regimen produced an average free-drug time above MIC of approximately 55%, supporting regimen rationality while also highlighting the limits of uncontrolled pharmacokinetic evidence.

• Everolimus (RAD001): From Growth Arrest to Cell Death

  2026-08-08

  Everolimus (RAD001) is an mTOR pathway inhibitor whose biological impact can be misread when viability is treated as synonymous with cell death. This guide combines pathway pharmacology with a paired assay framework for distinguishing cancer cell proliferation inhibition, cytostasis, and apoptosis in translational research.

• AMG 487: Practical CXCR3 Antagonist Workflows

  2026-08-07

  AMG 487 is a selective CXCR3 antagonist for dissecting chemokine-driven migration, calcium signaling, and macrophage polarization. Its strongest use-case is a state-aware workflow that combines pharmacology with LAMP1 and autophagy measurements rather than treating CXCR3 signaling as a single, context-independent pathway.

• Partial BACE Inhibition Reduces Amyloid β Without Synaptic L

  2026-08-07

  Satir et al. (2020) demonstrate that partial inhibition of β-secretase (BACE) can significantly decrease amyloid β (Aβ) production without impairing synaptic transmission in cultured neurons. Their findings suggest that moderate reduction of Aβ, akin to the natural protective Icelandic APP mutation, may avoid the adverse cognitive effects seen in previous clinical trials, informing more nuanced therapeutic strategies for Alzheimer's disease.

• ARID1A Loss Drives Osimertinib Resistance via PTEN/Akt Axis

  2026-08-06

  This study reveals that loss of ARID1A in lung adenocarcinoma epigenetically suppresses PTEN transcription, leading to Akt pathway activation and resistance to osimertinib. The findings highlight the ARID1A-PTEN-Akt signaling axis as a critical determinant of drug sensitivity and suggest new avenues for overcoming resistance in EGFR-mutant lung cancer.

453 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page